Abbvie Reports Positive Result for Telisotuzumab-Vedotin (Teliso-V) in P-II (LUMINOSITY) Study for the Treatment of NSCLC
Shots:
- The P-II study evaluates Teliso-V in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)
- The results of the study revealed that c-Met high patients had ORR of 35% as per independent central review (ICR), mOS of 14.6mos., and mDoR of 9mos. while 23% ORR per ICR, mDoR of 7.2mos. and mOS of 14.2mos. was observed in c-Met intermediate patients
- The company is currenlty recruiting patients for the P-III (TeliMET NSCLC-01) trial investigating Teliso-V as monotx. in patients with previously treated c-Met overexpressing EGFR wild type non-squamous NSCLC
Ref: PR Newswire | Image: AbbVie
Related News:- AbbVie’s Telisotuzumab Vedotin (Teliso-V) Receives the US FDA’s Breakthrough Therapy Designation for Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
